Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr 19;39(25):4781–4797. doi: 10.1038/s41388-020-1284-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — a Antiproliferative effect of neratinib in MCF7, MCF7 LTED, T47D, T47D LTED and HCC1428 LTED and their corresponding palbociclib-resistant (PalboR) derivatives. Data represents % viable cells compared with vehicle control for each cell line. Error bars represent mean ± SEM. b Effect of escalating concentrations of fulvestrant both in the presence or absence of neratinib (500 nM) in MCF7, MCF7 LTED, T47D, T47D LTED and HCC1428 LTED and their corresponding palbociclib-resistant (PalboR) cell lines. Data represents % viable cells. Error bars represent mean ± SEM. c Schematic representation of the effect of CDK4/6 inhibition and cross-talk with receptor tyrosine kinase signalling pathway. d Immunoblotting showing expression levels of several cell cycle, growth factor signalling and ER-regulated markers in MCF7 LTED^PalboR cell lines following single treatment with palbociclib (1 μM) or in combination with neratinib (500 nM) over a time course of 24 h. e Immunobloting showing abundance of nuclear ER in MCF7 LTED^PalboR cell lines after treatment with palbociclib (1 μM), neratinib (500 nM) or the combination of both.